Hello Part-time Trader…👋

Premium Stock Alerts is here with your pre-market cheat sheet. In today's issue, we delve into:

• Fed's Latest Announcements: Understand the Federal Reserve's recent decisions and economic outlook, and how they might influence the markets.

• Volume Anomalies: Identify stocks witnessing unusual trading volumes, pointing to potential opportunities or risks.

• Top Pre-Market Movers: Identify early winners poised for a strong market opening.

• Market Indices & Sector Overview: Get a snapshot of key market indices and sector performances to gauge the day's potential trends.

• FDA Approvals & Upcoming Decisions: Keep an eye on the latest FDA approvals and crucial upcoming decisions affecting biotech and pharmaceutical stocks.

Now, let's dive into today's edition for a closer look at the insights and analysis that will shape your trading decisions.

Happening Today

✓ 08:30 AM ET – GDP (QoQ) (Q1)

✓ 08:30 AM ET – Initial Jobless Claims

✓ 08:30 PM ET – Continuing Jobless Claims

✓ 08:30 PM ET – Goods Trade Balance (Mar)

✓ 08:30 PM ET – Retail Inventories Ex Auto (Mar)

PREMARKET SNAPSHOT 📈

Stock futures are mixed today, with NASDAQ 100 leading the gainers at 0.31%.

SECTOR SNAPSHOT ✨

Today's market is a mixed bag. Consumer Discretionary shines with a 0.5% rise, while Industrials take a hit, falling 0.79%.

Unusual Volume

📈 Chicken Soup for the Soul Entertainment Inc (CSSE) jumped 179.25% to $0.43 on a whopping 214.87 million shares traded after receiving a letter from The Nasdaq Stock Market informing the Company that its securities may be delisted from the Nasdaq Capital Market due to the fact the its Annual Report on Form 10-K for fiscal year ended December 31, 2023 had not been filed yet.

📈 Investors went wild, sending BranchOut Food Inc (BOF) stock soaring 77.78% to $2.08 on a massive volume of 107.08 million shares after the company announced third contract with Nation’s largest retailer, to total $8M in annualized revenue.

📈 Abnormal activity shook Amesite Inc (AMST), pushing it up 67.50% to $3.35 on a whopping 70.38 million shares traded after announcing the beta release of NurseMagic™, an innovative and proprietary app designed for nurses.

📈 Cyngn Inc (CYN) stock recently closed -6.49% lower at $0.11 on substantial volume of 50.79 million shares. This unusual activity came after the company announced pricing of $5.0 million firm commitment public offering of common stock.

📈 Pineapple Energy Inc (PEGY) decrease by -9.36% in a single trading session, with abnormally high trading volume of 41.57 million shares.

Premarket Movers

reAlpha Tech Corp. (AIRE) experiences a substantial 35.34% surge in pre-market trading after announcing the launch of Claire, the real estate industry’s first generative AI-powered, zero-commission Smart Buyer’s Agent.

American Airlines Group Inc. (AAL) sees a significant 5.60% increase, reaching a pre-market price of $14.70 after reporting Q1 2024 financial results.

ImmunityBio, Inc. (IBRX) demonstrates a noteworthy 7.22% surge, with a pre-market price of $5.16 after the company released positive overall survival results of Anktiva combined with Checkpoint Inhibitors in Non-Small Cell Lung Cancer.

Important FDA 

Recently Announced

ImmunityBio (IBRX) achieved a significant milestone on April 23, 2024, with the FDA approval of their drug Anktiva (formerly N-803). This marks a major advancement in the treatment of BCG-unresponsive non-muscle invasive bladder cancer, a particularly challenging form of the disease.

Johnson & Johnson (JNJ) made headway on April 5, 2024, as the FDA granted a broader application for their drug Carvykti. The drug is now approved for treating relapsed or refractory multiple myeloma, offering new hope for patients with this aggressive cancer.

Bristol-Myers Squibb Co. (BMY) celebrated a win on April 5, 2024, with the FDA approval of their drug Opdivo. When combined with cisplatin-based chemotherapy, Opdivo represents a significant step forward in managing unresectable or metastatic urothelial carcinoma.

Upcoming Announcements

Aquestive Therapeutics Inc. (AQST) awaits the FDA's eagerly anticipated decision on Libervant, a potential game-changer for managing difficult-to-control seizure clusters in young children (ages 2-5). The drug could offer a new and effective option, with a verdict expected on April 28, 2024.

XOMA Corporation (XOMA) anxiously awaits the FDA's announcement on tovorafenib, a drug holding promise for treating relapsed or progressive pediatric low-grade glioma (pLGG). This challenging diagnosis for both patients and families could see renewed hope with a positive decision on April 30, 2024. The drug has the potential to become a significant advancement in pediatric oncology.

X4 Pharmaceuticals, Inc (XFOR) anticipates a potentially groundbreaking decision from the FDA on April 30, 2024. Mavorixafor, being evaluated for use in patients aged 12 and above, could become a major breakthrough in treating WHIM syndrome, a rare immunodeficiency disorder.

Happy investing,

Maeve Grace
Editor In Chief
Premium Trade Alerts

Important: This newsletter does not provide investment advice. The stocks mentioned should not be taken as recommendations. Your investments are solely your decisions.

Disclosure: I hold no positions in any companies mentioned, either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I have no business relationship with any company whose stock is mentioned in this article.